NCT00481845View on ClinicalTrials.gov

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Breast Cancer
Interventions
DRUG

Vandetanib

300 mg daily

DRUG

Anastrozole

1 mg daily

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Stanford University

OTHER